Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

6000

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
EGFR Gene Mutation
ALK Gene Mutation
ROS1 Gene Mutation
MET Gene Mutation

Interventions

DRUG: Osimertinib
DRUG: Alectinib 150 MG
DRUG: Crizotinib 250 MG
DRUG: Savolitinib, Crizotinib.
DRUG: Chemotherapy

Sponsor

Hunan Province Tumor Hospital